istradefylline (Nourianz) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central KEGG MeSH PubChem

Active Ingredient History

NOW
  • Now
Istradefylline is a first-in-class adenosine A2A receptor antagonist antiparkinsonian agent and has been marketed as the brand name NOURIAST® in Japan since May 30, 2013. NOURIAST is indicated for the improvement of wearing-off phenomena in patients with Parkinson’s disease on concomitant treatment with levodopa-containing products.   NCATS

Chemistry

  • SMILES: CCN1C2=C(N(C)C(\C=C\C3=CC(OC)=C(OC)C=C3)=N2)C(=O)N(CC)C1=O
  • InChIKey: IQVRBWUUXZMOPW-PKNBQFBNSA-N
  • Mol. Mass: 384.429
  • ALogP: 2.12
  • ChEMBL Molecule:
    istradefylline  
More Chemistry

Pharmacology

Drug Pricing (per unit)

United States

$36.6513 - $36.6691
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

8-(2-(3,4-dimethoxyphenyl)ethenyl)-1,3-diethyl-3,7-dihydro-7-methyl-1h-purine-2,6-dione | istradefylline | kw6002 | kw 6002 | kw-6002 | nouriast

Organizations (8)

Research & Development (8)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (6)

Approved Indications (1)


 

Parkinson Disease (approved 2013)

Experimental Indications - Clinical Trial Phases 1-4 (6)


 

Liver Diseases (Phase 1)

Movement Disorders (Phase 2)

Parkinson Disease (Phase 3)

Restless Legs Syndrome (Phase 2)

Sleep Wake Disorders (Phase 2)

Substance-Related Disorders (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 25
  • # of Trial Organizations: 8

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue